Predictors of deterioration in health‐related quality of life in Parkinson's disease: Results from the DATATOP trial
Identifieur interne : 003257 ( Main/Merge ); précédent : 003256; suivant : 003258Predictors of deterioration in health‐related quality of life in Parkinson's disease: Results from the DATATOP trial
Auteurs : Connie Marras [Canada] ; Michael P. Mcdermott [États-Unis] ; Paula A. Rochon [Canada] ; Caroline M. Tanner [États-Unis] ; Gary Naglie [Canada] ; Anthony E. Lang [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2008-04-15.
Descripteurs français
- Wicri :
- geographic : Canada, États-Unis.
English descriptors
- KwdEn :
- Activities of Daily Living, Aged, Canada, Cognition Disorders (complications), Cognition Disorders (diagnosis), Cohort Studies, Depressive Disorder (complications), Depressive Disorder (diagnosis), Disease Progression, Female, Follow-Up Studies, Health‐related quality of life, Humans, Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson's disease, Predictive Value of Tests, Psychological Tests, Quality of Life, Randomized Controlled Trials as Topic (statistics & numerical data), Retrospective Studies, SF‐36., Selegiline (therapeutic use), Tocopherols (therapeutic use), United States.
- MESH :
- chemical , therapeutic use : Selegiline, Tocopherols.
- geographic : Canada, United States.
- complications : Cognition Disorders, Depressive Disorder, Parkinson Disease.
- diagnosis : Cognition Disorders, Depressive Disorder.
- drug therapy : Parkinson Disease.
- physiopathology : Parkinson Disease.
- statistics & numerical data : Randomized Controlled Trials as Topic.
- Activities of Daily Living, Aged, Cohort Studies, Disease Progression, Female, Follow-Up Studies, Humans, Male, Middle Aged, Predictive Value of Tests, Psychological Tests, Quality of Life, Retrospective Studies.
Abstract
The aim of this study was to investigate factors associated with decline in health‐related quality of life in Parkinson's disease, by a retrospective cohort study from referral centers in Canada and the United States. Subjects were patients with early Parkinson's disease (N = 362) enrolled in a clinical trial of deprenyl (selegiline) and tocopherol (DATATOP) and followed prospectively. The main outcome measure was change in health‐related quality of life using SF‐36 Mental and Physical Component Summary scores. The mean interval between SF‐36 measurements was 1.7 ± 0.1 years, beginning 5 to 6 years after enrolment into the trial. In multivariable analysis, baseline Hamilton Depression Scale scores and self‐rated cognitive function were associated with subsequent decline in Physical Component Summary scores, while older age and Schwab and England activities of daily living scores were associated with decline in Mental Component Summary scores. The Postural Instability Gait Disorder score was the only variable found to decline concurrently with HRQOL. Our results suggest that depression, self‐rated cognitive function, and one's degree of functional independence are predictors of subsequent changes in HRQOL. Our focus in clinical care needs to be broadened beyond assessing and treating Parkinsonism, recognizing the impact of mood, cognition and function on HRQOL. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21853
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001179
- to stream Istex, to step Curation: 001179
- to stream Istex, to step Checkpoint: 001235
- to stream PubMed, to step Corpus: 002385
- to stream PubMed, to step Curation: 002385
- to stream PubMed, to step Checkpoint: 002130
- to stream Ncbi, to step Merge: 001F74
- to stream Ncbi, to step Curation: 001F74
- to stream Ncbi, to step Checkpoint: 001F74
Links to Exploration step
ISTEX:D1A72ABB38AA31844602649EBF065E2AD457F5F5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Predictors of deterioration in health‐related quality of life in Parkinson's disease: Results from the DATATOP trial</title>
<author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name>
</author>
<author><name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael P." last="Mcdermott">Michael P. Mcdermott</name>
</author>
<author><name sortKey="Rochon, Paula A" sort="Rochon, Paula A" uniqKey="Rochon P" first="Paula A." last="Rochon">Paula A. Rochon</name>
</author>
<author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name>
</author>
<author><name sortKey="Naglie, Gary" sort="Naglie, Gary" uniqKey="Naglie G" first="Gary" last="Naglie">Gary Naglie</name>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:D1A72ABB38AA31844602649EBF065E2AD457F5F5</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1002/mds.21853</idno>
<idno type="url">https://api.istex.fr/document/D1A72ABB38AA31844602649EBF065E2AD457F5F5/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001179</idno>
<idno type="wicri:Area/Istex/Curation">001179</idno>
<idno type="wicri:Area/Istex/Checkpoint">001235</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Marras C:predictors:of:deterioration</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:18076084</idno>
<idno type="wicri:Area/PubMed/Corpus">002385</idno>
<idno type="wicri:Area/PubMed/Curation">002385</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002130</idno>
<idno type="wicri:Area/Ncbi/Merge">001F74</idno>
<idno type="wicri:Area/Ncbi/Curation">001F74</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001F74</idno>
<idno type="wicri:Area/Main/Merge">003257</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Predictors of deterioration in health‐related quality of life in Parkinson's disease: Results from the DATATOP trial</title>
<author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael P." last="Mcdermott">Michael P. Mcdermott</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Rochon, Paula A" sort="Rochon, Paula A" uniqKey="Rochon P" first="Paula A." last="Rochon">Paula A. Rochon</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Kunin‐Lunenfeld Applied Research Unit, Baycrest Centre for Geriatric Care, University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Institute for Clinical and Evaluative Sciences, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name>
<affiliation wicri:level="2"><country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>The Parkinson's Institute, Sunnyvale</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Naglie, Gary" sort="Naglie, Gary" uniqKey="Naglie G" first="Gary" last="Naglie">Gary Naglie</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Clinical Decision Making and Health Care, Toronto General Research Institute, University Health Network, University of Toronto, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of General Internal Medicine, University Health Network, University of Toronto, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Geriatrics Program, Toronto Rehabilitation Institute, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, Management and Evaluation, University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2008-04-15">2008-04-15</date>
<biblScope unit="vol">23</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="653">653</biblScope>
<biblScope unit="page" to="659">659</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">D1A72ABB38AA31844602649EBF065E2AD457F5F5</idno>
<idno type="DOI">10.1002/mds.21853</idno>
<idno type="ArticleID">MDS21853</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living</term>
<term>Aged</term>
<term>Canada</term>
<term>Cognition Disorders (complications)</term>
<term>Cognition Disorders (diagnosis)</term>
<term>Cohort Studies</term>
<term>Depressive Disorder (complications)</term>
<term>Depressive Disorder (diagnosis)</term>
<term>Disease Progression</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Health‐related quality of life</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson's disease</term>
<term>Predictive Value of Tests</term>
<term>Psychological Tests</term>
<term>Quality of Life</term>
<term>Randomized Controlled Trials as Topic (statistics & numerical data)</term>
<term>Retrospective Studies</term>
<term>SF‐36.</term>
<term>Selegiline (therapeutic use)</term>
<term>Tocopherols (therapeutic use)</term>
<term>United States</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Selegiline</term>
<term>Tocopherols</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Canada</term>
<term>United States</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Cognition Disorders</term>
<term>Depressive Disorder</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Cognition Disorders</term>
<term>Depressive Disorder</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Randomized Controlled Trials as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Activities of Daily Living</term>
<term>Aged</term>
<term>Cohort Studies</term>
<term>Disease Progression</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Predictive Value of Tests</term>
<term>Psychological Tests</term>
<term>Quality of Life</term>
<term>Retrospective Studies</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term>
<term>États-Unis</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The aim of this study was to investigate factors associated with decline in health‐related quality of life in Parkinson's disease, by a retrospective cohort study from referral centers in Canada and the United States. Subjects were patients with early Parkinson's disease (N = 362) enrolled in a clinical trial of deprenyl (selegiline) and tocopherol (DATATOP) and followed prospectively. The main outcome measure was change in health‐related quality of life using SF‐36 Mental and Physical Component Summary scores. The mean interval between SF‐36 measurements was 1.7 ± 0.1 years, beginning 5 to 6 years after enrolment into the trial. In multivariable analysis, baseline Hamilton Depression Scale scores and self‐rated cognitive function were associated with subsequent decline in Physical Component Summary scores, while older age and Schwab and England activities of daily living scores were associated with decline in Mental Component Summary scores. The Postural Instability Gait Disorder score was the only variable found to decline concurrently with HRQOL. Our results suggest that depression, self‐rated cognitive function, and one's degree of functional independence are predictors of subsequent changes in HRQOL. Our focus in clinical care needs to be broadened beyond assessing and treating Parkinsonism, recognizing the impact of mood, cognition and function on HRQOL. © 2007 Movement Disorder Society</div>
</front>
</TEI>
<double doi="10.1002/mds.21853"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Predictors of deterioration in health‐related quality of life in Parkinson's disease: Results from the DATATOP trial</title>
<author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name>
</author>
<author><name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael P." last="Mcdermott">Michael P. Mcdermott</name>
</author>
<author><name sortKey="Rochon, Paula A" sort="Rochon, Paula A" uniqKey="Rochon P" first="Paula A." last="Rochon">Paula A. Rochon</name>
</author>
<author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name>
</author>
<author><name sortKey="Naglie, Gary" sort="Naglie, Gary" uniqKey="Naglie G" first="Gary" last="Naglie">Gary Naglie</name>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:D1A72ABB38AA31844602649EBF065E2AD457F5F5</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1002/mds.21853</idno>
<idno type="url">https://api.istex.fr/document/D1A72ABB38AA31844602649EBF065E2AD457F5F5/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001179</idno>
<idno type="wicri:Area/Istex/Curation">001179</idno>
<idno type="wicri:Area/Istex/Checkpoint">001235</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Marras C:predictors:of:deterioration</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Predictors of deterioration in health‐related quality of life in Parkinson's disease: Results from the DATATOP trial</title>
<author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael P." last="Mcdermott">Michael P. Mcdermott</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Rochon, Paula A" sort="Rochon, Paula A" uniqKey="Rochon P" first="Paula A." last="Rochon">Paula A. Rochon</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Kunin‐Lunenfeld Applied Research Unit, Baycrest Centre for Geriatric Care, University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Institute for Clinical and Evaluative Sciences, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name>
<affiliation wicri:level="2"><country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>The Parkinson's Institute, Sunnyvale</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Naglie, Gary" sort="Naglie, Gary" uniqKey="Naglie G" first="Gary" last="Naglie">Gary Naglie</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Clinical Decision Making and Health Care, Toronto General Research Institute, University Health Network, University of Toronto, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of General Internal Medicine, University Health Network, University of Toronto, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Geriatrics Program, Toronto Rehabilitation Institute, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, Management and Evaluation, University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2008-04-15">2008-04-15</date>
<biblScope unit="vol">23</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="653">653</biblScope>
<biblScope unit="page" to="659">659</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">D1A72ABB38AA31844602649EBF065E2AD457F5F5</idno>
<idno type="DOI">10.1002/mds.21853</idno>
<idno type="ArticleID">MDS21853</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Health‐related quality of life</term>
<term>Parkinson's disease</term>
<term>SF‐36.</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The aim of this study was to investigate factors associated with decline in health‐related quality of life in Parkinson's disease, by a retrospective cohort study from referral centers in Canada and the United States. Subjects were patients with early Parkinson's disease (N = 362) enrolled in a clinical trial of deprenyl (selegiline) and tocopherol (DATATOP) and followed prospectively. The main outcome measure was change in health‐related quality of life using SF‐36 Mental and Physical Component Summary scores. The mean interval between SF‐36 measurements was 1.7 ± 0.1 years, beginning 5 to 6 years after enrolment into the trial. In multivariable analysis, baseline Hamilton Depression Scale scores and self‐rated cognitive function were associated with subsequent decline in Physical Component Summary scores, while older age and Schwab and England activities of daily living scores were associated with decline in Mental Component Summary scores. The Postural Instability Gait Disorder score was the only variable found to decline concurrently with HRQOL. Our results suggest that depression, self‐rated cognitive function, and one's degree of functional independence are predictors of subsequent changes in HRQOL. Our focus in clinical care needs to be broadened beyond assessing and treating Parkinsonism, recognizing the impact of mood, cognition and function on HRQOL. © 2007 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial.</title>
<author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada. connie.marras@utoronto.ca</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael P" last="Mcdermott">Michael P. Mcdermott</name>
</author>
<author><name sortKey="Rochon, Paula A" sort="Rochon, Paula A" uniqKey="Rochon P" first="Paula A" last="Rochon">Paula A. Rochon</name>
</author>
<author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M" last="Tanner">Caroline M. Tanner</name>
</author>
<author><name sortKey="Naglie, Gary" sort="Naglie, Gary" uniqKey="Naglie G" first="Gary" last="Naglie">Gary Naglie</name>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="doi">10.1002/mds.21853</idno>
<idno type="RBID">pubmed:18076084</idno>
<idno type="pmid">18076084</idno>
<idno type="wicri:Area/PubMed/Corpus">002385</idno>
<idno type="wicri:Area/PubMed/Curation">002385</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002130</idno>
<idno type="wicri:Area/Ncbi/Merge">001F74</idno>
<idno type="wicri:Area/Ncbi/Curation">001F74</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001F74</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial.</title>
<author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada. connie.marras@utoronto.ca</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael P" last="Mcdermott">Michael P. Mcdermott</name>
</author>
<author><name sortKey="Rochon, Paula A" sort="Rochon, Paula A" uniqKey="Rochon P" first="Paula A" last="Rochon">Paula A. Rochon</name>
</author>
<author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M" last="Tanner">Caroline M. Tanner</name>
</author>
<author><name sortKey="Naglie, Gary" sort="Naglie, Gary" uniqKey="Naglie G" first="Gary" last="Naglie">Gary Naglie</name>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living</term>
<term>Aged</term>
<term>Canada</term>
<term>Cognition Disorders (complications)</term>
<term>Cognition Disorders (diagnosis)</term>
<term>Cohort Studies</term>
<term>Depressive Disorder (complications)</term>
<term>Depressive Disorder (diagnosis)</term>
<term>Disease Progression</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Predictive Value of Tests</term>
<term>Psychological Tests</term>
<term>Quality of Life</term>
<term>Randomized Controlled Trials as Topic (statistics & numerical data)</term>
<term>Retrospective Studies</term>
<term>Selegiline (therapeutic use)</term>
<term>Tocopherols (therapeutic use)</term>
<term>United States</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Selegiline</term>
<term>Tocopherols</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Canada</term>
<term>United States</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Cognition Disorders</term>
<term>Depressive Disorder</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Cognition Disorders</term>
<term>Depressive Disorder</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Randomized Controlled Trials as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Activities of Daily Living</term>
<term>Aged</term>
<term>Cohort Studies</term>
<term>Disease Progression</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Predictive Value of Tests</term>
<term>Psychological Tests</term>
<term>Quality of Life</term>
<term>Retrospective Studies</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term>
<term>États-Unis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The aim of this study was to investigate factors associated with decline in health-related quality of life in Parkinson's disease, by a retrospective cohort study from referral centers in Canada and the United States. Subjects were patients with early Parkinson's disease (N = 362) enrolled in a clinical trial of deprenyl (selegiline) and tocopherol (DATATOP) and followed prospectively. The main outcome measure was change in health-related quality of life using SF-36 Mental and Physical Component Summary scores. The mean interval between SF-36 measurements was 1.7 +/- 0.1 years, beginning 5 to 6 years after enrolment into the trial. In multivariable analysis, baseline Hamilton Depression Scale scores and self-rated cognitive function were associated with subsequent decline in Physical Component Summary scores, while older age and Schwab and England activities of daily living scores were associated with decline in Mental Component Summary scores. The Postural Instability Gait Disorder score was the only variable found to decline concurrently with HRQOL. Our results suggest that depression, self-rated cognitive function, and one's degree of functional independence are predictors of subsequent changes in HRQOL. Our focus in clinical care needs to be broadened beyond assessing and treating Parkinsonism, recognizing the impact of mood, cognition and function on HRQOL.</div>
</front>
</TEI>
</PubMed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003257 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 003257 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Merge |type= RBID |clé= ISTEX:D1A72ABB38AA31844602649EBF065E2AD457F5F5 |texte= Predictors of deterioration in health‐related quality of life in Parkinson's disease: Results from the DATATOP trial }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |